Palvella Therapeutics

Forecast & Rating15 analysts currently cover Palvella Therapeutics, with about 100.0% giving a positive rating — meaning they expect the stock to rise. The average price target is $230.53, about 46.6% upside from the current price of $157.24. Price targets span a fair range, indicating some disagreement among institutions. Historically, about 45.1% of past price targets were eventually met, which adds credibility. For you, this means most professionals who study Palvella Therapeutics closely still see room for the stock to rise. Data as of Aug 31, 2026; for reference only and not investment advice.